Literature DB >> 11561807

Relative potency of telithromycin, azithromycin and erythromycin against recent clinical isolates of gram-positive cocci.

A L Barry1, P C Fuchs, S D Brown.   

Abstract

A ketolide (telithromycin), an azalide (azithromycin) and a macrolide (erythromycin) were tested against 2,733 isolates of gram-positive cocci gathered from 11 different medical centers. Telithromycin was active against erythromycin-resistant staphylococci that were susceptible to clindamycin but was not active against those that were resistant to clindamycin. More than 99% of all Streptococcus pneumoniae and Streptococcus pyogenes isolates were susceptible to 1 microg/ml of telithromycin including erythromycin- and azithromycin-resistant strains. Telithromycin was not only more potent than azithromycin against macrolide-susceptible strains, it was also active against most macrolide-resistant strains. Although the prevalence of macrolide-resistant pneumococci increased from 19% to 27% between 1997 and 1999, macrolide resistance among other gram-positive cocci did not change substantially in that 2-year period.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561807     DOI: 10.1007/s100960100532

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.

Authors:  Pamela R Tessier; Holly M Mattoes; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 2.  The macrolide antibiotic renaissance.

Authors:  George P Dinos
Journal:  Br J Pharmacol       Date:  2017-08-10       Impact factor: 8.739

3.  Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae.

Authors:  C Betriu; E Culebras; M Gómez; I Rodríguez-Avial; B A Sánchez; M C Agreda; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 4.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Antibiotics for treatment of resistant gram-positive coccal infections.

Authors:  Hossam Al-Tatari; Nahed Abdel-Haq; Pimpanada Chearskul; Basim Asmar
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 5.319

Review 6.  Azithromycin through the Lens of the COVID-19 Treatment.

Authors:  Georgia G Kournoutou; George Dinos
Journal:  Antibiotics (Basel)       Date:  2022-08-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.